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Abstract: We aimed to report the implementation of a phenylketonuria (PKU) transition program
and study the effects of follow-up with an adult team on metabolic control, adherence, and loss of
follow-up. Fifty-five PKU patients were analysed in the study periods (SP): 2 years before (SP1)
and after the beginning of adult care (SP2). Retrospective data on metabolic control and number
of clinic appointments were collected for each SP, and protein intakes were analysed. In SP2, three
patients (6%) were lost to follow-up. There was a small but statistically significant increase in median
number of annual blood spots from SP1 to SP2: 11 (7–15) vs. 14 (7–20); p = 0.002. Mean ± SD of
median blood Phe remained stable (525 ± 248 µmol/L vs. 552 ± 225 µmol/L; p = 0.100); median %
of blood Phe < 480 µmol/L decreased (51 (4–96)% vs. 37 (5–85)%; p = 0.041) and median number
of clinic appointments increased from SP1 to SP2: (5 (4–6) vs. 11 (8–13); p < 0.001). No significant
differences were found regarding any parameter of protein intake. Our results suggest that the
implementation of an adult service was successful as impact on metabolic control was limited and
attendance remained high. Continuous dietetic care likely contributed to these results by keeping
patients in follow-up and committed to treatment.
Keywords: phenylketonuria; transition to adult care; metabolic control; adherence
1. Introduction
Phenylketonuria (PKU) is an inborn error of phenylalanine (Phe) metabolism [1]. Early
diagnosis and implementation of a Phe restricted diet have drastically improved clinical
prognosis [1], and the PKU European guidelines state that treatment and follow-up should
be maintained in adulthood [2]. However, the growing adult population with PKU is still
understudied and the impact of PKU in the ageing process is unknown [3]. PKU in adult-
hood has been associated with neurological and neuropsychiatric issues such as deficits in
executive function, tremor, depression, anxiety, and white matter abnormalities [4–6], but
comorbidities affecting other body systems are also reported [7–9].
Adherence to the Phe-restricted diet becomes increasingly difficult from adolescence
onwards [10]. Obstacles include poor palatability of protein substitutes [11,12], limited
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food choice, difficulties with food preparation, and severe restrictions on social life [13–15].
This can be particularly challenging for patients with classical PKU with a low tolerance of
Phe and natural protein, who still need a very strict diet in adulthood [2]. Studies have
consistently found deterioration of metabolic control with age in PKU [16–19]. A study in
the USA highlighted that while most patients up to 12 years old had average Phe levels
within target range, the same was true for only 49% of teenagers, 41% of young adults and
31% of patients ≥30 years old [20]. A high percentage of adult patients cease contact with
their metabolic team, they stop attending clinic appointments, and are consequently lost to
follow-up [19–21]. Generally, female are more likely than male patients to adhere to some
dietary restriction and remain in follow-up, which is probably associated with concerns
about maternal PKU syndrome [19].
It is appropriate that adults with PKU should expect to be treated in an adult environ-
ment, with adult teams trained to manage their issues and comorbidities [22]. However,
many adult clinics do not offer a service to adults with PKU [23]. Thereby patients remain
in paediatric care, commonly ‘breaching’ the ‘follow-up’ rules of paediatric hospitals [19]
and are left without specialised medical care due to lack of experienced adult physicians.
Other patients may have been discharged to their General Practitioner and community
services as their paediatric hospitals are no longer able to support them. Fortunately, some
new adult services are currently being commissioned but some older patients may go years
without receiving appropriate follow-up, and many may abandon their dietary treatment.
Patients who discontinue treatment are often unwilling or unable to go back on the diet
later in life, while adult teams may struggle to contact them so they can resume specialist
care [24]. Failure to follow-up adult patients with PKU will also increase the probability of
metabolic control deterioration which will be a lost opportunity to further understand the
impact of the ageing process in PKU.
Careful transition from paediatric to adult metabolic services is imperative, enabling
the patient and their family to develop confidence and build a relationship with their
adult team. Failure can lead to patient dissatisfaction and poor engagement [25]. The
European PKU guidelines [2] recommend starting the transition process at 12 years of
age. The transfer to an adult treatment centre commonly occurs between the patient age
16 to 18 years, although the optimal time for transfer should be determined for each case
depending on individual circumstances and patient maturity [2]. Because patients with
PKU may have decreased autonomy [26], a later transfer may be advantageous as they
are likely to be more mature and self-sufficient, making it easier to handle changes in
healthcare provision.
The transition process should aim to develop the practical skills and knowledge
required by an adolescent, allowing them to become gradually more responsible for man-
aging their own condition while their caregivers slowly step down [15]. Transition should
continue even after the transfer between hospitals, as it is better if the first few appoint-
ments are conducted jointly by both members of the paediatric and adult metabolic teams.
These aspects of transitional care have been associated with better outcomes and could
maximize retention in adult services [27]. Some additional useful considerations that will
assist in the transition process were recently published as a recommendation from the
European PKU Guidelines Group [28].
Little is known about the effect of transition on PKU outcome. It is difficult to study
as a separate entity as management guidelines and treatments are constantly evolving
with new therapies such as tetrahydrobiopterin (BH4) and more recently Pegvaliase [29].
However, absence of blood Phe deterioration, patient satisfaction and patients remaining
in follow-up post-transition are usually seen as encouraging, and are useful indicators of
transition outcome [30,31].
In this paper we aim to report the establishment of paediatric and adult services for
PKU care at our centre, and the implementation of a transition program from the paediatric
to the adult setting. Specifically, we study the effects of the first two years of follow-up by
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an adult team on the quality of metabolic control, patient adherence to treatment, and loss
of follow-up.
2. Materials and Methods
2.1. Follow-Up Care Protocol for Patients with PKU
Newborn screening for PKU was implemented in Portugal in 1979. It was located
at Centro de Genética Médica, where a team of nutritionists, psychologist and geneticist
provided treatment for patients with PKU. In addition, a paediatrician from the nearest
paediatric hospital (Hospital Central Especializado de Crianças Maria Pia) visited Centro de
Genética Médica, but treatment was mainly managed by nutritionists.
Patients > 18 years were left without specialized adult medical care, as they were
‘too old’ to see a paediatrician according to hospital policy. These patients were kept
under the supervision of nutritionists, psychologist and geneticist. Moreover, a group of
adult physicians and nurses from Centro Hospitalar Universitário do Porto who had received
training in inherited metabolic disorders, started working with Centro de Genética Médica in
2009. In the following years, some adult patients with PKU were assigned to one physician,
but medical follow-up was still infrequent.
In 2013, Centro de Genética Médica and the paediatric hospital were merged with Centro
Hospitalar Universitário do Porto and moved to a new facility in 2016. Structured paediatric
and adult services for PKU care were soon created and medical follow-up became more
frequent. The paediatric team included metabolic paediatricians and nurse who cared for
patients approximately up to 18 years old at the paediatric hospital. In the adult team, the
physicians and nurses were able to slowly incorporate more patients in follow-up at the
adult hospital. This went on until eventually, every adult patient with PKU had access to
specialized medical care that focused on health promotion, prevention and management of
co-morbidities. The same nutritionists, psychologist and geneticist who had provided care
until then became part of both paediatric and adult teams and have continued to follow-up
all the patients ever since the merge.
In the paediatric as well as in the adult care protocol, each clinic visit now consisted
of multiple appointments (medical, nutritional, psychological) and the collection of blood
spots for Phe measurement. We were, thereby, able to optimize each visit and reduce the
frequency of clinic visits, thus minimising burden on patients. Patients also undergo an
annual nutritional status evaluation that involves anthropometric assessments, body com-
position analysis by bioelectrical impedance and measurement of several blood markers of
nutritional status.
Once the paediatric and adult services were fully established, the first patients to
experience a transition from their paediatric to their adult physician were transferred
in 2015. We have since implemented a more structured transition protocol (Figure 1).
Transition is now initiated around 14 years old, as patients are encouraged and educated to
become more involved in the management of their condition and undertake self-care. We
educate patients and families about the need for transition and provide information about
the adult team and follow-up care in the adult service. We also reassure them there will still
be no costs to pay for protein substitutes and special low protein foods. Patients meet their
new adult physician once before transfer at the paediatric hospital, in a joint consultation
with their paediatrician. Transfer occurs at approximately 18 years old, although the exact
timing is agreed with each patient and caregivers.
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2.2. Participants
We identified all patients with PKU at Centro de Genética Médica/Centro Hospitalar
Universitário do Porto who started follow-up with an adult physician until 2015, and who
had received treatment at our centre for a minimum of 2 years prior (n = 67). The date of
the first medical appointment with the adult physician was used to define the beginning of
adult care for each patient.
2.3. Study Design
This was an observational, retrospective, longitudinal study. All data was gathered
from patient clinical records. Retrospective data regarding metabolic control, and frequency
of clinic appointments were collected and analysed in two different study periods (SP):
2 years before and after the start of adult care (SP1 and SP2, respectively). Data on natural
protein, protein equivalent from protein substitute, total protein and dietary Phe intakes
from when patients entered adult care and after SP2 were compared. The study design is
illustrated in Figure 2.
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2.4. Data Collection
2.4.1. Metabolic Control
Fasting blood Phe concentrations were measured from dried blood spots and analysed
using tandem mass spectrometry. Patients were requested to take at least one blood spot at
home every month, according to national consensus [32]. Patients could occasionally be
asked to do this more frequently depending on metabolic control (for example, if there were
sudden changes or fluctuations in blood Phe), changes in dietary prescriptions, during
illness, among other reasons. The annual number of returned blood spots, the median blood
(Phe) and percentage of measurements within the treatment range (<480 µmol/L [32]) were
calculated for each patient in SP1 and SP2. Patients who had a BH4 loading test in SP1 or
SP2 were identified, as this may have affected metabolic control.
2.4.2. Frequency of Clinic Appointments
Electronic clinical records were analysed to determine the number of medical appoint-
ments (with a paediatrician in SP1, or an adult physician in SP2) and nutrition appointments
attended and not attended for each SP. Each medical and nutrition appointment was iden-
tified and calculated separately, even though they were usually scheduled for the same day.
Patients who did not return to clinic after the first appointment with an adult physician
were considered lost to follow-up.
2.4.3. Protein Intake
Protein intake at the start of adult care was estimated at the last nutrition appointment
before the first encounter with the new adult physician. Protein intake after SP2 was
estimated at the first nutrition appointment after the end of SP2.
Diet history questionnaires and body weight measurements were performed to calcu-
late daily protein intake. Natural protein (g/kg/day), protein equivalent from protein sub-
stitute (g/kg/day), total protein (g/kg/day) and Phe (mg/day) intakes were included in
data collection. Anthropometric assessments were performed as previously described [33].
However, only weight (which was assessed with a single measurement) was used to
quantify protein intakes in g/kg body weight.
2.4.4. Ethical Statement
All the data collected had ethical approval from the Ethics Committee of Centro
Hospitalar Universitário do Porto, EPE, on 18th May 2015, to the investigation project TNSPKU
(Trends in nutritional status of patients with phenylketonuria), with the reference 2015.101
(092-DEFI/087-CES). Patients gave written informed consent.
2.4.5. Statistical Analysis
Statistical analysis was done using IBM SPSS Statistics 25 for Windows. The Kolmogorov-
Smirnov test was performed to verify the normal distribution of variables. Categorical
variables were presented as absolute values or percentages, while continuous variables
were presented as means ± SDs or as medians (P25–P75). Paired t-test and Wilcoxon
test were used to identify differences between variables with normal and non-normal
distribution, respectively. Statistical significance was considered when p < 0.05.
3. Results
3.1. Patient Demographics
A total of 12 patients were excluded: 10 were late diagnosed and had inconsistent
dietary adherence, whilst 2 initiated sapropterin treatment during the study period, which
may have influenced metabolic control.
Therefore, 55 patients (54.5% females) were studied. The disease severity was classified
according to the Portuguese consensus [32], using neonatal blood (Phe): 5 patients (9.1%)
had hyperphenylalaninemia (blood (Phe) < 360 µmol/L), 26 patients (47.3%) mild PKU
(blood (Phe) ≥ 360 µmol/L and ≤1200 µmol/L) and 24 patients (43.6%) classical PKU
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(blood (Phe) > 1200 µmol/L). Mean ± SD age at the start of adult care was 23.3 ± 4.3 years
(range 18–33 years).
Table 1 describes gender, disease severity, age and year of the first appointment with
an adult physician, and enrolment to a BH4 loading test. Patients initiated follow-up with
an adult physician between 2011 and 2015 but more than half started in 2013 (n = 31). No
BH4 loading tests were performed in SP1, but they were performed in almost half of the
patients (n = 24) in SP2. No patients started pharmacological treatment in this period.
Table 1. Gender, disease severity, age and year of the first appointment with an adult physician, and enrolment to a BH4
loading test.




Disease severity, n (%)
Hyperphenylalaninemia 5 (9.1)
Mild PKU 26 (47.3)
Classical PKU 24 (43.6)
Age at the first appointment with an adult physician,
years (mean ± SD (range)) 23.3 ± 4.3 (18–33)






BH4 loading test, n (%)
SP1 0 (0)
SP2 24 (43.6)
PKU, phenylketonuria; BH4, tetrahydrobiopterin; SP1, study period 1; SP2, study period 2.
Three patients (6% of the total sample; 2 mild PKU females and 1 classical PKU male)
did not return to clinic after the first appointment with the adult physician. They were
considered lost to follow-up, resulting in a final sample of 52 patients. There was one
pregnancy in SP2, which was unplanned and unfortunately resulted in miscarriage.
3.2. Blood Phenylalanine Control
Blood Phe control during the study is presented in Table 2. There was a 27% increase
in the median annual number of analysed blood spots from SP1 to SP2 (11 (7–15) vs.
14 (7–20); p = 0.002), while the mean ± SD of the median blood (Phe) remained stable
(525 ± 248 µmol/L vs. 552 ± 225 µmol/L; p = 0.100). The percentage of blood Phe
measurements within the treatment range (<480 µmol/L) significantly decreased in SP2
(51 (4–96)% vs. 37 (5–85)%; p = 0.041).
Table 2. Metabolic control of patients from the final sample (n = 52). Results are expressed as median
(P25–P75) or mean ± SD. p < 0.05 was considered significant.
SP1 (n = 52) SP2 (n = 52) p
Annual number of blood spots, n 11 (7–15) 14 (7–20) 0.002
Median blood (Phe), µmol/L 525 ± 248 552 ± 225 0.100
(Phe) measurements < 480 µmol/L, % 51 (4–96) 37 (5–85) 0.041
SP1, study period 1; SP2, study period 2; Phe, phenylalanine.
After stratifying the sample and analysing only the subjects who remained in follow-
up and did not have a BH4 loading test in SP2 (n = 28), the annual number of blood
spots increased by 18%, but it did not reach statistical significance (11 (8–16) vs. 13 (6–19);
p = 0.374). In contrast, there was a slight but significant increase in the median blood Phe in
this subset of patients (375 (236–672) µmol/L vs. 412 (319–728) µmol/L; p = 0.001), while
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the percentage of blood Phe measurements within the therapeutic range decreased, and
was statistically significant (91 (16–100)% vs. 77 (12–97)%; p = 0.012).
3.3. Follow-Up
As demonstrated in Table 3, the frequency of nutrition and medical appointments
increased in SP2. Respectively for SP1 vs. SP2, patients had 5 (3–6) vs. 7 (5–8) nutrition
appointments (p < 0.001) and 0 (0–1) vs. 4 (3–5) medical appointments (p < 0.001). In fact,
73% of patients did not have any scheduled appointments with a physician in SP1 (data
not shown). A small but significant increase was also seen in the number of total missed
appointments, with a median attendance of 100% in SP1 to 91% in SP2 (data not shown),
but overall attendance was excellent in both SP1 and SP2.
Table 3. Frequency of clinic visits in SP1 and SP2 (n = 52). Results are expressed as median (P25–P75).
p < 0.05 was considered significant.
SP1 (n = 52) SP2 (n = 52) p
Attended appointments, n
Nutrition 5 (3–6) 7 (5–8) <0.001
Medical 0 (0–1) 4 (3–5) <0.001
Total 5 (4–6) 11 (8–13) <0.001
Missed appointments, n
Nutrition 0 (0–1) 0 (0–1) 0.014
Medical 0 (0–0) 0 (0–1) 0.001
Total 0 (0–1) 1 (0–2) <0.001
SP1, study period 1; SP2, study period 2.
3.4. Dietary Intake
Table 4 shows that protein and Phe intakes at the beginning of adult care and after
SP2 were similar. There was a slight decrease in total protein intake and Phe daily intake
increased, but these differences did not reach statistical significance.
Table 4. Daily protein and Phe intakes (n = 52). Results are expressed as median (P25–P75). p < 0.05
was considered significant.
Entering Adult Care (n = 52) After SP2 (n = 52) p
Natural protein, g/kg/day 0.46 (0.35–0.88) 0.46 (0.28–0.94) 0.873
Protein equivalent, g/kg/day 0.85 (0.47–1.10) 0.83 (0.43–1.05) 0.066
Total protein, g/kg/day 1.51 (1.26–1.66) 1.34 (1.07–1.54) 0.194
Phe, mg/day 1210 (830–2311) 1318 (763–2935) 0.278
SP2, study period 2; Phe, phenylalanine.
4. Discussion
In this retrospective review of follow-up by an adult team for two years, patients
remained in follow-up with a slight deterioration in blood Phe control. Most patients
did not have specialized medical care in the two years prior to being assigned an adult
physician. However, the same nutritionists provided continuous care both before and after
structured paediatric and adult services were in place, and overall adherence was good
throughout the study. Very few patients were lost to follow-up and frequency of blood Phe
testing increased in the adult setting.
There were only 6% of patients lost to follow-up after the first appointment with an
adult physician. In another study, one adult clinic reported losing contact with 11% of
patients with PKU, although this referred to a 10-year period [31]. The number of patients
who did not return to our clinic was too small to see any gender differences. We had
predicted that more male patients would abandon care compared with females because of
maternal PKU concerns, similarly to what was described in an international survey [19].
Structured transition programs in services for other disorders have reported contrasting
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results. In one paper, all patients with type 1 diabetes remained in follow-up three years
after transfer [34]. Other programs documented dropout rates of 9% (rheumatology [35])
and 22% (sickle cell disease [36]). We understand that, in some centres patients may
continue to be under the care of paediatric teams, but adult service establishment will be in
a better position to manage and monitor adult medical issues [7,9].
Blood spots were returned more frequently in SP2. Some of this was associated
with BH4 loading tests, as these involved close monitoring of blood (Phe) to accurately
determine Phe tolerance variations and its impact on metabolic control [37]. However, after
excluding patients enrolled for a BH4 loading test, there was still a tendency for increased
number of blood spots, although not reaching statistical significance. In the adult care
protocol, clinic visits often included the collection of blood samples by a nurse for blood
Phe measurement. Thereby, it is possible that the more regular follow-up in adult care may
have improved blood spot return since the frequency of appointments ranged from every
2 months to every 4–6 months. Patients were also encouraged to track their blood Phe levels
at home frequently, allowing physicians and patients to better understand their biochemical
phenotype. The three adult physicians were supportive of diet for life treatment, so they
were fully committed to scheduling regular clinic visits and prescribing the blood Phe
measurements requests, according to what the team agreed for each individual patient.
Every month, the metabolic team met to discuss each patient scheduled to attend, while
also sharing good practices and training between the paediatric and adult team.
There was a lower percentage of Phe measurements below 480 µmol/L in SP2. In
patients who did not have a BH4 loading test, there was also a small increase in their
median blood Phe. Statistically, this represents a slight but significant deterioration of
metabolic control, although it is uncertain whether it could have significant clinical impact.
We expected some deterioration of blood Phe control with increasing age [17,18,20,38,39]
regardless of changes in healthcare, but moving to an adult setting may have contributed to
this tendency [40]. In contrast, one short term study documented improved median blood
Phe post-transfer [30], but the authors based this result on limited blood Phe measurements.
Protein intake when patients entered adult care versus after SP2 remained unchanged.
There were no significant differences for daily natural protein, protein equivalent from
protein substitute, total protein and Phe intakes. This suggests that patients maintained
stable dietary intakes and continued to take the prescribed protein substitutes after receiv-
ing treatment in an adult setting for two years. This was not surprising as patients were
seen by the same nutritionists and received consistent dietary advice. Also, the new adult
team members were completely aligned with the paediatric approach to ensure the same
treatment ethos was maintained in adulthood.
In both SPs, frequency of outpatient visits exceeded the minimum requirement of
two or one per year (for ages 12–18 years or ≥18 years, respectively) as recommended by
the European PKU Guidelines [2]. Despite the frequent visits, however, the percentage of
patients who chose not to attend appointments was very low throughout the study. Clinic
visits became more frequent in SP2 due to additional nutrition appointments (5 in SP1 vs.
7 in SP2), related to the preparation process for loading tests with BH4 [33]. Medical follow-
up was also more frequent in SP2 as most patients did not have medical appointments in
SP1. Before 2013, the medics working in collaboration with Centro de Genética Médica did
not follow-up patients with PKU frequently unless their clinical condition required medical
care. The merge with Centro Hospitalar Universitário do Porto allowed the adult physicians
to slowly start seeing more adult patients in the following years, as well as more often than
in the past. The fact that the patients in this sample saw their adult physician for the first
time between 2011 and 2015 therefore clarifies why most patients did not have medical
follow-up in the two years prior. This lack of medical appointments also suggests that
these patients did not exhibit signs of medical issues requiring close medical surveillance
in this period.
We are uncertain if a team of nutritionists and psychologists specializing in adult care
could potentially provide better care for adult patients, as opposed to the same professionals
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providing lifelong care. Adults require a more patient-focused approach, unlike paediatric
care which is very family-oriented [41]. Specialists in adult healthcare may also have more
training and experience dealing with specific issues of this population, such as pregnancy,
depression, co-morbidities and health conditions associated with ageing. When asked
about the challenges of receiving care in a paediatric facility, adult patients with PKU
highlighted the lack of access to adult-oriented resources, while the main benefit was the
familiarity and positive relationships with the paediatric team [22]. Leaving paediatric
specialists and changing to new healthcare professionals can induce anxiety and be a major
barrier for transfer [42,43], and establishing relationships with a completely new group of
professionals can be overwhelming for both patients and families. Therefore, we aimed
to limit the addition of new members to the adult team. We were able to keep the same
nutritionists in the paediatric and adult teams; nutritionists have a pivotal role in the
management of PKU.
This study had several limitations. Patient numbers were small, and all data was
collected retrospectively. BH4 loading tests in SP2 led to more frequent clinic visits, and may
have influenced frequency of blood testing, metabolic control, and adherence. No patient
satisfaction surveys were conducted to assess patient acceptance of their new adult care
service. These patients started follow-up with an adult physician before the paediatric and
adult services were fully established. Their age also surpasses what is usually considered
acceptable for a transition to adult care. As a result, these findings may not reflect the
reality of patients who are currently undergoing transition at Centro Hospitalar Universitário
do Porto. Finally, it would have been important to compare our results with other models
of transition for patients with PKU.
5. Conclusions
The model adopted in our centre for implementing adult care for patients with PKU
resulted in no significant loss of follow-up. There was, however, some deterioration in
blood Phe control that should not be overlooked. Maintenance of most members of the
metabolic team probably contributed to these results, but high mean age and exposure to a
BH4 loading test added ambiguity to the outcome of this study. Prospective multicentre
studies are needed to better understand the real impact of transition in patients with
PKU. Future research should also address aspects such as low adherence to treatment in
adults, and if new therapies will help motivate patients to remain follow-up in adult clinics
post-transition.
Author Contributions: Conceptualization, J.C.R.; methodology, J.C.R.; formal analysis, M.P.; investi-
gation, M.P. and É.J.P.; writing—original draft preparation, M.P.; writing—review and editing, M.F.A.,
É.J.P., C.C., S.R., A.G., R.R., E.M., A.B., A.M. and J.C.R.; visualization, M.P.; supervision, M.F.A., A.M.
and J.C.R. All authors have read and agreed to the published version of the manuscript.
Funding: This article was supported by National Funds through FCT-Fundação para a Ciência e a
Tecnologia, I.P., within CINTESIS, R&D Unit (reference UIDB/4255/2020).
Institutional Review Board Statement: The study was conducted according to the guidelines of the
Declaration of Helsinki, and approved by the Ethics Committee of Centro Hospitalar Universitário do
Porto, EPE (TNSPKU, 2015.101 (092-DEFI/087-CES), 18th May 2015).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author. The data are not publicly available due to privacy and ethical reasons.
Nutrients 2021, 13, 799 10 of 11
Conflicts of Interest: M.F.A. received grants from Glutamine, Nutricia, Merck Serono, BioMarin,
Orphan, and Lifediet to attend congress and for education. A.M. has received research funding
and honoraria from Nutricia, Vitaflo International, BioMarin, Mevalia, and Pharma Galen. She is a
member of the European Nutrition Expert Panel (BioMarin), and a member of the following advisory
boards: the European PKU Group Board (BioMarin), Element (Danone-Nutricia), Excemed, Arla,
and Applied Pharma Research. J.C.R. is member of the European Nutrition Expert Panel (BioMarin)
and of the advisory boards of Applied Pharma Research and Nutricia. He has received speaker’s
fees from Applied Pharma Research, Merck Serono, BioMarin, Nutricia, Vitaflo, Cambrooke, PIAM,
and Lifediet.
References
1. Blau, N.; van Spronsen, F.J.; Levy, H.L. Phenylketonuria. Lancet 2010, 376, 1417–1427. [CrossRef]
2. Van Wegberg, A.M.J.; MacDonald, A.; Ahring, K.; Bélanger-Quintana, A.; Blau, N.; Bosch, A.M.; Burlina, A.; Campistol, J.; Feillet,
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